




Please Note: Medical Necessity Prior Authorization may be overridden for both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager.

PRIOR AUTHORIZATION **BYPASS** **Afinitor® (everolimus)**

Bypass the Prior Authorization by Modifying the following Prescription Forms to the Patient's Needs



Name _____
 Address _____

Rx

*COMPLETE PRIOR
 AUTHORIZATION
 FORMS*

Dx: BREAST CANCER

D 48.60

MD _____
 Signature _____

Name _____
 Address _____

Rx

MD _____
 Signature _____



Prescriber Information

Last Name: <input type="text"/> DEA/NPI: <input type="text"/> Phone <input type="text"/>	First Name <input type="text"/> Specialty: <input type="text"/> Fax <input type="text"/>
--	--

Member Information

Last Name: <input type="text"/> Member ID Number <input type="text"/>	First Name <input type="text"/> DOB: <input type="text"/>
--	--

Medication Information:

Drug Name and Strength: <input type="text"/> Diagnosis: <input type="text"/>	Quantity and Dosing: <input type="text"/> Duration: <input type="text"/>
---	---

When advised below, please include all requested fax documentation (lab results, etc.) when submitting this Prior Authorization fax form; not submitting requested documentation could delay the clinical review process.

Afinitor Prior Authorization Form

Initial Therapy		
You must answer ALL of the following questions		
1. What is the patient's diagnosis? (Please Circle) <ul style="list-style-type: none"> • Advanced Renal Cell Carcinoma • Subependymal giant cell astrocytoma (SEGA) • Advanced neuroendocrine tumors • Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) • Other diagnosis: _____ 		
ADVANCED RENAL CELL CARCINOMA		
2. Is the patient 18 years of age or older?	Y	N
3. Does the patient have a diagnosis of advanced renal cell carcinoma defined as greater than or equal to Stage T3a based on the American Cancer Society System? <i>Please provide documentation.</i>	Y	N
4. Has the patient tried and failed Nexavar, Sutent, or Votrient? <i>Please provide documentation.</i>	Y	N
SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA)		
2. Does the patient have a diagnosis of subependymal giant cell astrocytoma (SEGA)? <i>Please provide documentation.</i>	Y	N
3. Is SEGA associated with tuberous sclerosis (TS)? <i>Please provide documentation.</i>	Y	N



4. Is the patient a candidate for curative surgical resection?	Y	N
ADVANCED NEUROENDOCRINE TUMORS		
2. Is the patient 18 years of age or older?	Y	N
3. Does the patient have a diagnosis of advanced neuroendocrine tumors of pancreatic origin? <i>Please provide documentation.</i>	Y	N
4. Is the tumor unresectable, locally advanced, or metastatic?	Y	N
RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC)		
2. Does the patient have a diagnosis of renal angiomyolipoma associated with tuberous sclerosis complex (TSC)? <i>Please provide documentation.</i>	Y	N
3. Does the patient have documented tuberous sclerosis and renal angiomyolipoma(s) greater than or equal to 3 cm in length? <i>Please provide documentation.</i>	Y	N

Renewal Therapy		
You must answer ALL of the following questions		
1. What is the patient's diagnosis? (Please Circle)		
<ul style="list-style-type: none"> • Advanced Renal Cell Carcinoma • Subependymal giant cell astrocytoma (SEGA) • Advanced neuroendocrine tumors • Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) • Other diagnosis: _____ 		
ADVANCED RENAL CELL CARCINOMA		
2. Is the patient 18 years of age or older?	Y	N
3. Does the patient have a diagnosis of advanced renal cell carcinoma defined as greater than or equal to Stage T3a based on the American Cancer Society System? <i>Please provide documentation.</i>	Y	N
4. Has the patient tried and failed Nexavar, Sutent, or Votrient? <i>Please provide documentation.</i>	Y	N
SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA)		
2. Does the patient have a diagnosis of subependymal giant cell astrocytoma (SEGA)? <i>Please provide documentation.</i>	Y	N
3. Is SEGA associated with tuberous sclerosis (TS)? <i>Please provide documentation.</i>	Y	N
4. Is the patient a candidate for curative surgical resection?	Y	N
ADVANCED NEUROENDOCRINE TUMORS		
2. Is the patient 18 years of age or older?	Y	N
3. Does the patient have a diagnosis of advanced neuroendocrine tumors of pancreatic origin? <i>Please provide documentation.</i>	Y	N
4. Is the tumor unresectable, locally advanced, or metastatic?	Y	N
RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC)		
2. Has the patient's angiomyolipoma volume decreased by greater than or equal to 50% since initiating Afinitor therapy? <i>Please provide documentation.</i>	Y	N
3. Have there been any new developments of angiomyolipoma lesions that are greater than or equal to 1 cm?	Y	N
4. Has the kidney volume increased by more than 20%? <i>Please provide documentation.</i>	Y	N
5. Have there been any angiomyolipoma related bleeding greater than or equal to Grade 2? <i>Please provide documentation.</i>	Y	N



Please note, not all drugs/diagnoses are covered on all plans.

Comments: _____

Information given on this form is accurate as of this date.

Prior Authorization forms are located on the Cover Page. Print a new form for each request as forms are updated periodically.

Prescriber or Authorized Signature

Date

Authorized Medical Staff – Name/Title

Attention Healthcare Provider: If you would like to discuss this request with a medical professional, please contact the Prior Authorization Department whose numbers are found on the Cover Page,

I understand that USDoctor's use or disclosure of individually identifiable health information, whether furnished by me or obtained by another source such as medical providers, shall be in accordance with federal privacy regulations under HIPAA (Health Insurance Portability and Accountability Act of 1996).



Contact Information:

Telephone: (855)251.9116

Fax: (248)593.9575

Please Note: Medical Necessity Prior Authorization may be utilized to override both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager.

**PRIOR AUTHORIZATION FORM:
COVER PAGE**

MEMBER INFORMATION			
First Name		Last Name	
Plan			
Member ID		Date of Birth	
DRUG INFORMATION			
Drug Name			
Quantity		ICD-10	
Directions		Duration of Therapy	
Diagnosis			
PLEASE LIST ALTERNATIVE THERAPIES THAT HAVE BEEN ATTEMPTED AND ANY OTHER PERTINENT INFORMATION RELATED TO DRUG AND/OR DISEASE STATE. IF NOT PRESENT, WITHIN NORMAL LIMITS WILL BE USED FOR THE REVIEW.			
Medication/Failure Reason:			
IgE: _____			
ESR: _____ CRP: _____ # Joints: _____ %BSA: _____			
Height: _____ Weight: _____ BMI: _____			
HA1C: _____ Hemoglobin: _____ Hematocrit: _____ T-Score: _____			
Dialysis: _____ Long Term Care Facility: _____ Self Injecting: _____			
Stimulation test: _____ / _____ Growth velocity: _____ #Chemotherapy cycles/month: _____			
Mini-Mental Status Test: _____ Baseline Free testosterone/Total testosterone: _____ / _____			
HCV RNA viral load: _____ Viral Genotype: _____ ALT: _____			
PHYSICIAN INFORMATION			
Physician Signature		Date	
Physician Name		NPI #	
Phone Number		Fax Number	
Action Needed	Only mark Urgent when standard review time would seriously harm the member's life or health or ability to regain maximum function <input type="checkbox"/> Urgent <input type="checkbox"/> For Review	Pharmacy Fax	
The information contained in this facsimile message, including the attachments, may be privileged, may constitute inside information and is intended only for use of the addressee. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited and may be unlawful. If you have received this communication in error, please immediately notify me by replying to this message and destroy the original message.			